MLYS
Mineralys Therapeutics, Inc.
There isn't enough reported data to score MLYS yet.
MLYS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
MLYS's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
MLYS PE Valuation
MLYS has no meaningful PE right now: it lost money over the past year.
MLYS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect MLYS's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
MLYS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.28 | -$1.31 |
| Q2 2026 | -$4.16 | -$0.58 |
| Q1 2026 | -$1.97 | +$1.78 |
| Q4 2025 | -$2.29 | +$1.37 |
| Q3 2025 | -$2.97 | +$0.29 |
| Q2 2025 | -$3.58 | -$0.88 |
| Q1 2025 | -$3.75 | -$1.57 |
| Q4 2024 | -$3.66 | -$1.67 |
MLYS is still losing money, but less than at its worst: $4.28 per share over the past year, against $5.77 at its worst in late 2022.
MLYS Quarterly Revenue
MLYS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$43.1M | -$14.2M |
| Q2 2026 | -$32.6M | -$2.4M |
| Q1 2026 | -$39.5M | +$6M |
| Q4 2025 | -$37.9M | +$28.9M |
| Q3 2025 | -$28.9M | +$21.4M |
| Q2 2025 | -$30.2M | -$23K |
| Q1 2025 | -$45.5M | -$26.3M |
| Q4 2024 | -$66.8M | -$37.9M |
MLYS has burned cash in almost every quarter: −$153M over the past year, against −$171M the year before.
MLYS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5% | +4.3M shares |
| 1 year | +26% | +18.4M shares |
| 3 years | +124% | +49.2M shares |
MLYS has 89M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
MLYS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -52.2x | Net Cash |
| Q3 2022 | -65.7x | Net Cash |
MLYS has more cash than debt.
MLYS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 2.1 | Oversold |
MLYS's weekly RSI is 28 (oversold) and its Stochastic is 2 (oversold).
MLYS PE vs Healthcare Sector
MLYS has no meaningful PE right now: it lost money over the past year.
MLYS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.3 | 24% below |
| 20 week MA | $24.3 | 36% below |
| 50 week MA | $27.5 | 44% below |
| 100 week MA | $23.8 | 35% below |
MLYS is in a downtrend: it's below all four of its weekly moving averages, and 35% below its 100-week average.
MLYS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $18.4 | $8.60 | -53% |
| 2024 | $8.60 | $12.8 | +49% |
| 2025 | $12.8 | $37.1 | +190% |
| 2026 YTD | $37.1 | $15.5 | -58% |
MLYS's yearly returns have swung widely, from +190% in 2025 to −53% in 2023. It's down 58% so far in 2026.